Roger Fleischman, MD
Hematology & Oncology · Lexington, KYNPI 1902815814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,600 of the $11,694 with a category attached, or 65.0%. Pharmacyclics LLC, An Abbvie Company accounts for 70.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $8,346 and has fallen 65.0% since, to $2,919 in 2025.
Across 17 payments — averaging $687.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$8K
- Servier Pharmaceuticals LLC$3K
- Johnson & Johnson$257
- ADC Therapeutics America, Inc.$243
- AstraZeneca$135
- E.r. Squibb & Sons, L.L.C.$35
- plus $72 from 3 others
Across 33 payments — averaging $2918.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$83K
- Bristol Myers Squibb$13K
What the payments were for
- Consulting fees$2,72023%
- Speaking & faculty fees$7,60065%
- Travel & lodging$5014%
- Food & beverage$8737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 7 | $8,233 |
| Servier Pharmaceuticals LLC | 1 | $2,720 |
| Johnson & Johnson | 2 | $257 |
| ADC Therapeutics America, Inc. | 2 | $243 |
| AstraZeneca | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Beone Medicines USA, Inc. | 1 | $29 |
| Beigene USA, Inc. | 1 | $28 |
| Morphosys, US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,694 in reported general payments places this provider in the 75th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 96 | $1,225,153 |
| ImbruvicaIbrutinib | 36 | $526,987 |
| JaypircaPirtobrutinib | 17 | $332,893 |
| ScemblixAsciminib Hydrochloride | 11 | $238,934 |
| TasignaNilotinib Hcl | 17 | $219,339 |
| BrukinsaZanubrutinib | 16 | $209,170 |
| GleevecImatinib Mesylate | 13 | $129,326 |
| Imatinib Mesylate | 12 | $1,377 |
| Prednisone | 20 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $135 | $1,225,15396 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $8,233 | $526,98736 claims |
| Beigene USA, Inc.Brukinsa | $28 | $209,17016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Lexington
- Firas BadinLexington$1.6M
- Nicola JabbourLexington$563K
- John VillanoLexington$16K
- Christopher BurkeenLexington$13K
- Jessica CroleyLexington$12K
- Ayman QasrawiLexington$9K
- Ryan WoodsLexington$6K
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.